Aligos Therapeutics price target lowered to $70 from $75 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...
Aligos Therapeutics reports Q4 EPS ($13.08) vs ($5.50) last year
Reports Q4 revenue $629k, consensus $433.33k. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated ...
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...
IiTzTimmy, Verhulst, and more Apex stars land with new teams as ALGS offseason heats up
Rostermania rages on in North America with many of Apex's biggest names finding themselves new homes. With year five of the ...
Yahoo Finance3d
Aligos Therapeutics, Inc. (ALGS)
Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best ...
Nasdaq5d
ALIGOS THERAPEUTICS Earnings Preview: Recent $ALGS Insider Trading, Hedge Fund Activity, and More
ALIGOS THERAPEUTICS ($ALGS) is expected to release its quarterly earnings data on Monday, March 10th before market open, per Finnhub. Analysts are expecting revenue ...
Benzinga.com4mon
Aligos Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ALGS | Benzinga
Beam Therapeutics Begins Dosing in Phase I/II AATD Study Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational ...